| |
Oral GLP-1
Analogue
| Primary Indication |
Treatment of Type 2 diabetes
mellitus |
| Stage of Development |
Preclinical |
- Outlicensing opportunity
- providing oral formulation technology
to GLP-1 analogue
- Stimulates insulin formation
and release when blood glucose levels are
high
- Reduces glucose output from
the liver
- Improves insulin sensitivity
and the function of ß-cells
- Slows emptying of stomach
and reduces desire to eat
|
|
|
